Biodesix, Inc.
BDSX
$0.8622
$0.01221.44%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 65.56M | 60.90M | 54.85M | 49.09M | 44.03M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 65.56M | 60.90M | 54.85M | 49.09M | 44.03M |
| Cost of Revenue | 14.61M | 13.66M | 13.02M | 13.01M | 12.94M |
| Gross Profit | 50.96M | 47.25M | 41.83M | 36.08M | 31.08M |
| SG&A Expenses | 76.48M | 71.96M | 68.95M | 67.39M | 67.76M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.12M | 94.04M | 90.75M | 90.39M | 92.37M |
| Operating Income | -34.56M | -33.14M | -35.90M | -41.30M | -48.34M |
| Income Before Tax | -43.82M | -44.51M | -47.06M | -52.15M | -63.35M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -43.82 | -44.51 | -47.06 | -52.15 | -63.35 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.82M | -44.51M | -47.06M | -52.15M | -63.35M |
| EBIT | -34.56M | -33.14M | -35.90M | -41.30M | -48.34M |
| EBITDA | -29.26M | -28.55M | -31.94M | -37.97M | -45.09M |
| EPS Basic | -0.39 | -0.46 | -0.55 | -0.65 | -0.90 |
| Normalized Basic EPS | -0.24 | -0.29 | -0.34 | -0.40 | -0.52 |
| EPS Diluted | -0.39 | -0.46 | -0.55 | -0.65 | -0.90 |
| Normalized Diluted EPS | -0.24 | -0.29 | -0.34 | -0.40 | -0.52 |
| Average Basic Shares Outstanding | 462.96M | 396.37M | 347.71M | 328.31M | 293.79M |
| Average Diluted Shares Outstanding | 462.96M | 396.37M | 347.71M | 328.31M | 293.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
